Explainable machine learning prediction of edema adverse events in patients treated with tepotinib.

Autor: Amato F; Swiss Data Science Center (EPFL and ETH Zurich), Lausanne, Switzerland., Strotmann R; The healthcare business of Merck KGaA, Darmstadt, Germany., Castello R; Swiss Data Science Center (EPFL and ETH Zurich), Lausanne, Switzerland., Bruns R; The healthcare business of Merck KGaA, Darmstadt, Germany., Ghori V; Ares Trading S.A., Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany., Johne A; The healthcare business of Merck KGaA, Darmstadt, Germany., Berghoff K; The healthcare business of Merck KGaA, Darmstadt, Germany., Venkatakrishnan K; EMD Serono, Billerica, Massachusetts, USA., Terranova N; Quantitative Pharmacology, Ares Trading S.A., Lausanne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.

Publikováno v: Clinical and translational science [Clin Transl Sci] 2024 Sep; Vol. 17 (9), pp. e70010.

33P Real-world experience of MET TKI-induced peripheral edema

Autor: Ferrara, R., Vansteenkiste, J.F., Yang, X., Grossi, F., Melosky, B., Ahn, M-J., Calles, A., Chan, O.S.H., Han, B., Bulusu, V.R., Califano, R., Nishino, K., Ghori, V., Ronga, P., Berghoff, K., Vlassak, S., Le, X.

Publikováno v: In Journal of Thoracic Oncology April 2023 18(4) Supplement:S59-S60

Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.

Autor: Schwabe C; Auckland Clinical Studies Ltd, Auckland, New Zealand., Illes A; Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland., Ullmann M; Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland., Ghori V; Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland., Vincent E; Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland., Petit-Frere C; Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland., Monnet J; Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland., Racault AS; Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland., Wynne C; Christchurch Clinical Studies Trust Ltd, New Zealand.

Publikováno v: Expert review of clinical immunology [Expert Rev Clin Immunol] 2022 May; Vol. 18 (5), pp. 533-543. Date of Electronic Publication: 2022 Apr 10.

Effect of topical nitric oxide donor (0.2 % glyceryl trinitrate) on wound healing in diabetic wistar rats.

Autor: Ghori, V.¹, Mandavia, Divyesh¹, Patel, Tejas², Tripathi, C.¹ cbrtripathi@yahoo.co.in

Publikováno v: International Journal of Diabetes in Developing Countries. Mar2014, Vol. 34 Issue 1, p45-49. 5p. 1 Color Photograph, 2 Charts, 1 Graph.

Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial.

Autor: Lickliter J; Nucleus Network, Melbourne, Australia., Kanceva R; Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland. Electronic address: Radmila.Kanceva@fresenius-kabi.com., Vincent E; Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland., Schueler A; Biostatistics, Merck Healthcare, Darmstadt, Germany., Harrison-Moench E; Quantitative Pharmacology, Merck Healthcare, Darmstadt, Germany., Yue CS; Learn and Confirm, Inc., St-Laurent, Québec, Canada., Stahl M; Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland., Ullmann M; Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland., Ghori V; Biosimilars, Fresenius Kabi SwissBioSim, Eysins, Switzerland., Griffin P; School of Medicine, University of Queensland, Brisbane, Australia; Department of Medicine and Infectious Diseases, Mater Hospital and Mater Medical Research Institute, Brisbane, Queensland, Australia.

Publikováno v: Clinical therapeutics [Clin Ther] 2020 Aug; Vol. 42 (8), pp. 1508-1518.e1. Date of Electronic Publication: 2020 Jul 11.